1)plasminogen activator inhibitor 1纤溶酶原激活抑制物1
2)atherrosclerosis纤溶酶原激活抑制物-1
1.Objective Raising atherrosclerosis model, to observe the the local expression of angiotensin II (Ang II ), transforming growth factor-β1 (TGF-β1)、plasminogen activator inhibitor-1 (PAI-1) and type IV collagen in renal tissue and to approach the renal protective effect of Captopril and Valsartan through blocking renin-angiotonin system(RAS) on various level.目的建立动脉粥样硬化(atherosclerosis,AS)模型,观察在AS形成时肾脏组织中血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、纤溶酶原激活抑制物-1(plasminogen activator inhibitor-1,PAI-1)和Ⅳ型胶原蛋白的表达以及卡托普利与缬沙坦从不同水平阻断肾素-血管紧张素系统(renin-angiotonin system,RAS)后对肾脏的保护作用。
英文短句/例句
1.Relation between TNF-α in Adipose Tissue and Plasminogen Activator Inhibitor-1 in Plasma;脂肪组织中肿瘤坏死因子-α与血浆纤溶酶原激活抑制物-1相关性的研究
2.Expression of TNF-α protein in the omental and subcutaneous adipose tissue in obesity肥胖者网膜脂肪肿瘤坏死因子-α的表达与血浆纤溶酶原激活抑制物-1的相关性分析
3.Relationship between plasminogen activator inhibitor 1 and neuroblastoma纤溶酶原激活物抑制物1与神经母细胞瘤
4.Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases纤溶酶原激活物抑制剂-1与心血管疾病
5.Inhibitory effect of green tea polyphenols on plasminogen activator inhibitor-1 expression绿茶多酚对纤溶酶原激活物抑制剂-1表达影响
6.The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用
7.Research Progress of Plasminogen Activator Inhibitor One in Gestational Diabetes Mellitus纤溶酶原激活物抑制剂-1（PAI-1）与妊娠期糖尿病的研究
8.Change and Implication of PAI-1 in Coronary Heart Disease Patients after Glucose Load冠心病患者糖负荷后纤溶酶原激活物抑制物-1的变化及意义
9.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究
10.The relation of plasma plasminogen activator inhibitor activity and coronary heart disease纤溶酶原激活抑制物活性与冠心病发病关系
11.The Effect of Astragalus and Safflower Mixture on Expression of Plasminogen Activator Inhibitor 1 in Renal Tubulointerstitial Fibrosis in Rats with Unilateral Ureteral Obstruction;芪红合剂对肾间质纤维化模型大鼠肾组织中纤溶酶原激活物抑制物-1表达的影响
12.Plasma Concentrations of Matrix Metalloproteinase-9 and Plasminogen Activator Inhibitor-1 in Acute Coronary Syndromes;急性冠脉综合征金属蛋白酶-9与纤溶酶原激活物抑制物-1的关系研究
13.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
14.The Varity and Mechnisim of the Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes with Hypertriglyceridemia;伴高甘油三酯血症的2型糖尿病纤溶酶原激活物抑制物-1水平变化及机制探讨
15.The expression of plasminogen activator inhibitor 1 (PAI 1) gene in human astrocytomasG人脑星形细胞瘤纤溶酶原激活抑制因子1基因表达研究
16.A Preliminary Study on the Relationship between TM、PAI-1 and Carotid Artery Lesion in DM;血栓调节蛋白、纤溶酶原激活物抑制物-1与糖尿病颈动脉病变的关系
17.The clinical analysis on the homocystein and PAI-1 of 80 cases of the patients with metabolism synthesis drafts the merge apoplexy80例代谢综合征合并脑卒中患者同型半胱氨酸及纤溶酶原激活物抑制物-1检测分析
18.Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析
相关短句/例句
atherrosclerosis纤溶酶原激活抑制物-1
1.Objective Raising atherrosclerosis model, to observe the the local expression of angiotensin II (Ang II ), transforming growth factor-β1 (TGF-β1)、plasminogen activator inhibitor-1 (PAI-1) and type IV collagen in renal tissue and to approach the renal protective effect of Captopril and Valsartan through blocking renin-angiotonin system(RAS) on various level.目的建立动脉粥样硬化(atherosclerosis,AS)模型,观察在AS形成时肾脏组织中血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、纤溶酶原激活抑制物-1(plasminogen activator inhibitor-1,PAI-1)和Ⅳ型胶原蛋白的表达以及卡托普利与缬沙坦从不同水平阻断肾素-血管紧张素系统(renin-angiotonin system,RAS)后对肾脏的保护作用。
3)plasminogen activator inhibitor-1(PAI-1)纤溶酶原激活物抑制剂-1(PAI-1)
4)plasminogen activator inhibitor-1(PAI-1) gene纤溶酶原激活剂抑制物-1(PAI-1)基因
5)Plasminogen Activator Inhibitor-1 (PAI-1)纤溶酶原激活剂抑制物-1(PAI-1)
6)plasminogen activator inhibitor-1/biosythesis纤溶酶原激活剂抑制剂1/生物合成
延伸阅读
纤溶酶原激活剂分子式：CAS号：性质：是一组蛋白酶，使纤溶酶激活生成有活性的纤溶酶。它们主要包括：(1)组织纤溶酶激动剂(tPA)，一种丝氨酸蛋白酶，创伤或应激时从血管内皮释放入血，只有同纤维蛋白结合时才有激活纤溶酶原的活性；(2)尿激酶，对纤维蛋白选择性较低，是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌，可能参与清除沉积在管道内的纤维蛋白；(3)链激酶，临床上用于裂解纤维蛋白，其选择性较差，可作用于液相中的纤溶酶原，也可作用于纤维蛋白血块中的纤溶酶原，链激酶不是蛋白酶，但与纤溶酶原结合成复合物后构象改变，显示蛋白水解酶活性。
